Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics said today that the Chinese National Medical Products Administration (NMPA) has approved its BRCA1 and BRCA2 gene mutation detection kit.

The next-generation sequencing-based kit is designed for the qualitative detection of BRCA1 and BRCA2 mutations in patients with different cancer types including ovarian cancer and breast cancer, and is the first BRCA gene mutation detection product approved in China, AmoyDx said.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.